ROGER FRANKLIN, PhD

Partner
[email protected]

A scientist by training, since completing his doctoral work at Cambridge’s Laboratory of Molecular Biology (LMB), Roger has gained wide ranging experience across venture capital, investment banking and strategy consulting over almost two decades. At Hadean, Roger focuses on investments in the therapeutic space.

Roger sits/has sat on the board of multiple current and former Hadean portfolio companies, as director or observer, including Emergence Therapeutics (acquired by Eli Lilly in 2023), Cardior Pharmaceuticals (acquired by NovoNordisk in 2024 for up to c.€1bn), Contineum Therapeutics (Nasdaq IPO in 2024), Abliva, Step Pharma, Targed Biopharmaceuticals, Gesynta Pharma and Complement Therapeutics.

Prior to joining Hadean in 2018 to head up its Stockholm office, Roger was senior pharmaceutical and biotechnology analyst at Liberum, an investment bank in London during which time his recommendations delivered top quartile performance.